Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04859517 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ADG20 for the Prevention of COVID-19
A Phase 2 study, sponsored by Invivyd.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2,582
- Enrollment target
NCT04859517 is a Phase 2 study that was terminated before completion, run by Invivyd. The registered enrollment target is 2,582 participants.
The verdict
NCT04859517, a Phase 2 study, was terminated before completion, sponsored by Invivyd.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2,582 participants
- Enrollment target
Study Summary
This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
Interventions
- DRUG Placebo
- DRUG ADG20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,582 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2022-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04859517
The ClinicalTrials.gov registry entry for NCT04859517 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2,582 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invivyd, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04859517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04859517 about?
NCT04859517 is a clinical study titled "Evaluation of ADG20 for the Prevention of COVID-19". This placebo-controlled study is intended to evaluate ADG20's safety and ability to prevent COVID-19 infection.
What is the current status of trial NCT04859517?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2,582 participants. The study started on 2021-04-27. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT04859517?
The interventions under investigation include: Placebo (DRUG), ADG20 (DRUG).
Who is sponsoring clinical trial NCT04859517?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.